Roman Greifeneder

Roman Greifeneder serves as CTO & Regulator at Micropace Pty Ltd. Micropace Pty Ltd operates in the medical devices sector with approximately 28.0 employees. The company is headquartered in Sydney, New South Wales. Micropace Pty Ltd generates annual revenue of 7000000.0.

Industry & Role Insights

• • MessageCEO tracks 1,888 executives in the medical devices sector.
• • 3,176 executive contacts are available in New South Wales.
• • Our database includes 201,468 c suite-level executives.

cardiac stimulation electrophysiology pediatric pediatric cardiology medical equipment manufacturing cardiac stimulators arrhythmia management stimulus generator portable diagnostic ecg recorder patient safety bedside control multi-site pacing training videos remote monitoring clinical workflow touchscreen interface advanced pacing technology electrocardiogram patient leads customizable pacing distributor portal spar parts clinical training user manuals patient monitoring electrophysiologist tools real-time diagnostics cardiac protocols integrated systems remote control medical software wireless connectivity diagnostic accuracy ecg visualization research applications custom rtos comfort features system compatibility emergency pacing dial settings touch interface surgical aids clinical environment continuous operation battery backup hospital use cable connections vital signs monitoring software updates data management interventional cardiology high-frequency stimulation medical devices hospital & health care

YM

Yahia Megahed CEO at 360Imaging

HA

Hugo Azevedo Chief Technology Officer at 3B Scientific

MP

Marie-Laure Pochon CEO & President at 3DISC

KD

Khanh Duy Co-CEO at 3D-Side

K

Khanh Co-CEO at 3D-Side

Outreach Guidance — medical devices Sector

Executives like Roman Greifeneder in the medical devices sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Micropace Pty Ltd.

Roman Greifeneder's Position in the MessageCEO Database

• •Roman Greifeneder is 1 of 1 verified executive contact we track at Micropace Pty Ltd.
• •1,787 verified executive contacts in medical devices are in the MessageCEO database.
• •3,103 verified executive contacts in New South Wales are in the database.
• •21 verified contacts work at medical devices companies in the 28.0 employee range (same size as Micropace Pty Ltd).

Executive contact data compiled from public business filings, LinkedIn public profiles, company press materials, and verified outbound email testing. We do not publish personal addresses or sensitive identifiers. Methodology & sources · Removal requests handled at /remove-info · Updated July 2026.

How do I reach Roman Greifeneder directly?

Roman Greifeneder's verified email address is available to MessageCEO Pro subscribers. They currently serve as CTO & Regulator at Micropace Pty Ltd. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Roman Greifeneder work for?

Roman Greifeneder is CTO & Regulator at Micropace Pty Ltd, a company in the medical devices sector with 28.0 employees. The company is based in Sydney, New South Wales.

Can I pitch or sell to Roman Greifeneder?

As CTO & Regulator at Micropace Pty Ltd, Roman Greifeneder is a key decision-maker in the medical devices sector. MessageCEO Pro gives you verified email to reach Roman Greifeneder directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Roman Greifeneder in?

Roman Greifeneder works in the medical devices industry as CTO & Regulator at Micropace Pty Ltd. MessageCEO provides verified contact information for executives across all major industries.

Is Roman Greifeneder's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Roman Greifeneder's profile is kept up-to-date with the latest available information.

Last updated: July 30, 2026